Darzalex

Darzalex (daratumumab) is a monoclonal antibody used in the treatment of multiple myeloma. This subcutaneous medication targets specific proteins to help manage certain blood cancers.

Darzalex is primarily used for the treatment of multiple myeloma, a type of blood cancer. It works by targeting a protein called CD38, which is found on the surface of myeloma cells. This helps the immune system recognize and destroy these cancerous cells. Daratumumab is often used in combination with other therapies to enhance treatment outcomes.

Common effects of Darzalex may include infusion-related reactions such as fever, chills, and shortness of breath. Other possible effects include fatigue, nausea, and upper respiratory infections. These effects vary among individuals and are typically monitored by healthcare professionals.

Darzalex should be administered under the supervision of a healthcare provider. It is important to inform your doctor about any allergies or medical conditions before starting treatment. Regular monitoring is recommended to manage potential side effects and ensure safety.

Darzalex may interact with other medications, particularly those that affect the immune system. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol and certain supplements may also impact the effectiveness of daratumumab.